Accord Healthcare is a global pharmaceutical company and a Category Award Winner for Business Expansion, Product Launches, Research and Development and Social in the 2023 Pharmaceutical Technology Excellence Awards.

Accord Healthcare’s headquarters in the UK

Headquartered in the United Kingdom (UK), Accord Healthcare, Ltd. is one of the fastest growing pharmaceutical companies in Europe. Accord has one of the largest market footprints among European companies in its category ensuring that over 95% of European patients get access to vital medicines. Accord is committed to providing patients and healthcare professionals with high-quality medicines whilst continually looking for opportunities to innovate existing medicines to better meet patient needs. Accord is actively working on expansion of its specialty portfolio across 4 therapy areas – Oncology & Hematology, Autoimmune, CNS and Critical care. With this vision, Accord is planning to launch ~60 products which are currently under development over next 5 years across these therapy areas.

Accord Healthcare is a Category Award Winner in four areas in the 2023 Pharmaceutical Technology Excellence Awards – Business Expansion, Product Launches, Research and Development, and Social.

Accord’s commitment to increasing access to high-quality biosimilar medicines and its vision “We Make it Better” has given birth to a unique quest to find superior treatments and innovative solutions to improve patient care and patient outcomes across the world. To augment its presence in the speciality segment, Accord has one of the most enviable product portfolios in the industry with unrivalled investment in the licensing of new speciality products – including NCEs, biosimilars, new drug delivery systems, unique formulations, and niche brands, such as Orgovyx®, Europe’s first and only oral androgen deprivation therapy for men with advanced hormone-sensitive prostate cancer.

Accord’s Business Development (BD) team has been instrumental in leveraging Accord’s commercial infrastructure by building a broader franchise-focused portfolio through partnerships and achieving optimum utilization of resources to deliver sustainable revenues. During the last financial year, the company signed 15 in-licensing transactions towards this end, improving its standing in key markets. The sale from partnered programmes contributes ~21% to Accord EMENA revenues and Accord expects it to significantly increase in the next four years.

Accord Healthcare Management
Accord’s team at CPHI 2023

The key achievement of the BD team includes the launch of Orgovyx® in Europe. This deal embarks on Accord’s journey in the new chemical entity market in the EU. Accord anticipate Orgovyx® becoming a flagship brand in Accord’s oncology franchise. Other ground-breaking deal includes a strategic global collaboration agreement with Syna Therapeutics for the development and commercialization of the clinical-stage, biosimilar product LB-0702 to treat pathologies in the field of haematology. LB-0702 would form a distinctive part of Accord’s Haematology franchise as it has a lot of synergies with other Haematology treatments in Accord’s portfolio including Accofil® (filgrastim) and Pelgraz® (pegfilgrastim).

Another notable project saw the company launch Zolsketil®, the first generic version of Caelyx® in Europe. The medicine is a treatment for several cancer types including breast and ovarian cancer, multiple myeloma, and Kaposi’s sarcoma. Zolsketil® is a liposomal product which is believed to be able to penetrate the altered and often compromised vasculature of tumours.

Accord is also recognized in our Social category for its effort in supplying essential medicines to Ukraine. The company has a long-standing partnership with International Health Partners (IHP) but following the invasion of Ukraine, this had to rapidly adjust to the crisis.

Under the ‘Project Hope’ initiative, Accord pulled forward its entire annual donation of essential medicines within a week to send on to Ukraine. In 2023, the company provided more than 15,000 units of medicine for IHP and offered an extra 3,470 units in essential medicines to the Ukraine response. In addition, the company also sent humanitarian aid to the country’s Ministry of Health and organised charity initiatives.

Finally, the company also enhanced its Research and Development operations through the launch of Accord BioPharma – London, a state-of-the-art laboratory in London to support research activities.

Contact details

319 Pinner Road; North Harrow, London, Middlesex, HA1 4HF

United Kingdom